BAY 1834845
Phase 2
BayerBAY 1834845 is one of 13 therapeutic programs targeting COPD. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
15 competitors in COPD
#DrugCompanyPhaseTrials
1Spiriva
Boehringer IngelheimApproved
Striverdi Respimat
Boehringer IngelheimApproved
Daliresp
AstraZenecaPhase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Tezspire
AstraZenecaPhase 2
Fasenra
AstraZenecaPhase 3
Medrol
PfizerPreclinical
JNJ-77002
Johnson & JohnsonPhase 2
AZD7594
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for BAY 1834845. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company